Liquidia (NASDAQ:LQDA) Stock Price Expected to Rise, HC Wainwright Analyst Says

Liquidia (NASDAQ:LQDA) had its price objective increased by HC Wainwright from $50.00 to $55.00 in a report issued on Friday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. HC Wainwright’s target price points to a potential upside of 52.65% from the company’s current price. HC Wainwright also issued estimates for Liquidia’s Q4 2025 earnings at $0.33 EPS, FY2025 earnings at ($0.64) EPS, Q1 2026 earnings at $0.43 EPS, Q1 2026 earnings at $0.35 EPS, Q2 2026 earnings at $0.49 EPS, Q2 2026 earnings at $0.62 EPS, Q3 2026 earnings at $0.86 EPS, Q4 2026 earnings at $0.98 EPS, Q4 2026 earnings at $0.86 EPS, FY2026 earnings at $2.89 EPS, FY2027 earnings at $2.97 EPS, FY2028 earnings at $4.97 EPS, FY2029 earnings at $7.57 EPS and FY2030 earnings at $9.85 EPS.

LQDA has been the topic of several other reports. Needham & Company LLC reiterated a “buy” rating and issued a $52.00 price objective on shares of Liquidia in a research note on Wednesday, February 25th. Jefferies Financial Group boosted their price target on Liquidia from $45.00 to $55.00 and gave the company a “buy” rating in a research note on Tuesday, January 13th. Raymond James Financial reiterated a “strong-buy” rating on shares of Liquidia in a research report on Thursday. Zacks Research cut Liquidia from a “strong-buy” rating to a “hold” rating in a report on Friday, February 27th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Liquidia in a report on Thursday, January 22nd. Two analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has given a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat.com, Liquidia has an average rating of “Moderate Buy” and a consensus price target of $42.00.

Liquidia Price Performance

NASDAQ:LQDA opened at $36.03 on Friday. The company has a 50-day moving average of $37.10 and a 200-day moving average of $30.92. The company has a market capitalization of $3.13 billion, a price-to-earnings ratio of -43.41, a PEG ratio of 0.62 and a beta of 0.52. Liquidia has a 52 week low of $11.26 and a 52 week high of $46.67. The company has a debt-to-equity ratio of 6.19, a quick ratio of 1.96 and a current ratio of 2.20.

Liquidia (NASDAQ:LQDA) last posted its earnings results on Thursday, March 5th. The company reported $0.15 earnings per share for the quarter, missing analysts’ consensus estimates of $0.33 by ($0.18). Liquidia had a negative net margin of 43.53% and a negative return on equity of 237.79%. The business had revenue of $92.02 million during the quarter. The company’s revenue was up 3072.4% on a year-over-year basis. As a group, equities research analysts anticipate that Liquidia will post -1.51 earnings per share for the current fiscal year.

Insider Activity at Liquidia

In other Liquidia news, CAO Dana Boyle sold 1,580 shares of Liquidia stock in a transaction on Monday, January 26th. The shares were sold at an average price of $41.65, for a total transaction of $65,807.00. Following the completion of the sale, the chief accounting officer owned 178,848 shares of the company’s stock, valued at approximately $7,449,019.20. The trade was a 0.88% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Jason Adair sold 688 shares of the company’s stock in a transaction on Monday, January 26th. The shares were sold at an average price of $41.65, for a total transaction of $28,655.20. Following the sale, the insider owned 211,169 shares of the company’s stock, valued at $8,795,188.85. The trade was a 0.32% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 212,534 shares of company stock valued at $7,964,719 over the last quarter. 26.50% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Liquidia

A number of institutional investors have recently made changes to their positions in LQDA. Northwestern Mutual Wealth Management Co. acquired a new stake in Liquidia in the fourth quarter worth $25,000. NewEdge Advisors LLC bought a new stake in shares of Liquidia in the 2nd quarter valued at $25,000. Skandinaviska Enskilda Banken AB publ bought a new stake in shares of Liquidia in the 3rd quarter valued at $30,000. FNY Investment Advisers LLC acquired a new stake in Liquidia during the 3rd quarter worth $34,000. Finally, Covestor Ltd raised its stake in Liquidia by 41.9% during the 4th quarter. Covestor Ltd now owns 1,216 shares of the company’s stock worth $42,000 after buying an additional 359 shares during the period. 64.54% of the stock is owned by institutional investors and hedge funds.

Liquidia News Roundup

Here are the key news stories impacting Liquidia this week:

• Positive Sentiment: Commercial momentum and profitability — Liquidia reported YUTREPIA net product sales of $90.1M in Q4 and $148.3M for 2025, achieved a second consecutive profitable quarter (Q4 net income $14.6M) and positive adjusted EBITDA, signaling rapid launch adoption and improving unit economics. GlobeNewswire Release
• Positive Sentiment: Balance sheet strength — the company ended 2025 with ~$190.7M in cash, improving liquidity and backing management’s plan to fund commercial expansion and clinical programs from operations. Quiver Quant Summary
• Positive Sentiment: Analyst upgrades and higher price targets — several firms raised ratings/targets after the quarter (HC Wainwright to $55, Needham to $54, BTIG to $50, Wells Fargo to $44), which supports further upside and likely contributed to intraday buying. Benzinga Analyst Roundup
• Neutral Sentiment: Mixed EPS headlines — Liquidia reported GAAP EPS of $0.15 for Q4. That missed some sell‑side consensus figures (~$0.33) but beat other estimates (Zacks cited $0.08), creating mixed investor interpretation of the results. Zacks Coverage
• Neutral Sentiment: Earnings materials and management commentary available — the slide deck and transcript provide color on commercial adoption, prescriber metrics and plans to fund L606 and other programs; useful for assessing sustainability of the launch. Earnings Presentation (Seeking Alpha)
• Negative Sentiment: Initial market reaction to the EPS headline — shares gapped down on the earnings headline before rebounding, showing sensitivity to EPS versus revenue/profitability nuance. That initial gap indicates headline risk if future quarters miss expectations. DefenseWorld: Gap Down
• Negative Sentiment: Insider and institutional sales — recent filings and summaries show notable insider sell activity and some large institutional reductions, which can weigh on sentiment if sustained. Fool: SEC Filing

About Liquidia

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).